Background {#Sec1}
==========

Combined antiretroviral therapy (cART) has dramatically changed the prognosis of HIV-infection (Mocroft et al. [@CR22]; Weber et al. [@CR46]; Stöckle et al. [@CR38]; Jaggy et al. [@CR17]; Egger et al. [@CR11]). Given a timely diagnosis and treatment, life expectancy is most likely only marginally decreased compared to the general population (The Antiretroviral Therapy Cohort Collaboration [@CR40]). Therefore, with increasing age of HIV patients, long-term aspects such as neurotoxic effects of the virus and possibly of treatments gain importance (Robertson et al. [@CR30]). Losses in memory function, psychomotor speed and/or executive functions may occur at a higher frequency in HIV-infected compared to HIV-negative individuals (Robertson Robertson et al. [@CR30]). Cognitive disorders may negatively impact behaviour (Hinkin et al. [@CR16]), autonomy in everyday life, and risk behaviour (Gonzalez et al. [@CR13]; Vance & Struzick [@CR45]), leading to a diminished quality of life, lower adherence to cART and increased mortality. An early diagnosis of cognitive impairment is important for the initiation of cART which can then lead to improvements of neurocognitive symptoms (Cysique & Brew [@CR8]; Joska et al. [@CR19]; Tozzi et al. [@CR42]).

Definition of HIV-associated neurocognitive disorders (HAND) include three conditions: asymptomatic neurocognitive impairment (ANI), HIV-associated mild neurocognitive disorder (MND) and HIV-associated dementia (HAD). The prevalence of HAND was estimated to be 69% in HIV-infected persons in Switzerland who have been successfully treated for many years (Simioni et al. [@CR34]). In a US study (Robertson et al. [@CR29]), 21% of asymptomatic HIV-infected individuals fulfilled the criteria for ANI. Subjective reports about cognitive symptoms seem to be unreliable as up to 64% of asymptomatic patients were found to have cognitive impairment on neuropsychological assessment (Simioni et al. [@CR34]). A patient's underestimation of his own cognitive deficits is possibly due to a deficit in meta-memory, i.e. an executive dysfunction (Woods et al. [@CR47]). On the other hand, overestimation of one\'s own cognitive deficit is frequently seen in patients with depressive disorders (Rourke et al. [@CR31]; Carter et al. [@CR7]). Various screening tests like the HIV dementia scale (HDS) (Power et al. [@CR25]), the EXIT interview (Berghuis et al. [@CR4]), the Mental Alternation Test (Jones et al. [@CR18]), the modified Memorial Sloan-Kettering Scale (Marder et al. [@CR21]) or the International HIV Dementia Scale (IHDS) (Sacktor et al. [@CR33]) are used to identify HIV associated dementia, but these tests are not sensitive enough to detect the milder forms of HAND, i.e. ANI and MND, which are more prevalent in the HIV population (Singh et al. [@CR35]; Carey et al. [@CR6]). Recently, a score ≤ 14 points on the HDS (Power et al. [@CR25]) was found to yield a positive predictive value of HAND of 92% in complainers and 82% in non-complainers (Robertson et al. [@CR29]).

A useful screening test must have acceptable psychometric properties. Carey et al. (Carey et al. [@CR6]) were able to show that a combination of only two validated and standardised neuropsychological tests was better at classifying patients with cognitive disorders than the HDS alone. The neuropathological changes caused by the HIV infection mainly affect the fronto-striato-thalamo-cortical circuit, deficits in processing speed, executive functions and verbal episodic memory (Robertson et al. [@CR30]; Woods et al. [@CR47]). The most frequently used tests which are viewed as sensitive are the verbal memory tasks (Singh et al. [@CR35]; Carey et al. [@CR6]; Skinner et al. [@CR36]), the Trail Making Test part A and B ([@CR43]; Tombaugh et al. [@CR41]), the Grooved Pegboard Test (Ruff & Parker [@CR32]), the Digit Symbol Test (Härting et al. [@CR14]; Aster et al. [@CR2]), and the Digit Span forwards and backwards (Härting et al. [@CR14]). Combination of the Hopkins Verbal Learning Test -- Revised (HVLT-R) (Benedict et al. [@CR3]) with the Digit Symbol Test (Härting et al. [@CR14]; Aster et al. [@CR2]) or with the Grooved Pegboard Test (Ruff & Parker [@CR32]) non-dominant hand yielded a sensitivity of 75-78% and a specificity of 85-92%, respectively, in detecting mild cognitive disorders in HIV-infected individuals (Carey et al. [@CR6]).

Taking the above mentioned findings into account, the aims of this study were to evaluate the performance and to assess the acceptability of a German-language screening battery consisting of a short questionnaire and seven brief neuropsychological tests administered by trained nurses to screen for neurocognitive deficits in treated HIV-infected patients.

Methods {#Sec2}
=======

Ethical approval {#Sec3}
----------------

The protocol was approved by the local Ethics Committee "Ethikkommission beider Basel". All patients gave written informed consent.

Study participants {#Sec4}
------------------

Study participants were 30 HIV-infected individuals in care at the HIV Clinic of the University Hospital Basel, Switzerland meeting the following inclusion criteria: age ≥18 years, cART since ≥6 months, an undetectable HIV viral load (\<50 copies/mL) for ≥3 months, and to be a German native speaker. Exclusion criteria were auditory, visual or motor deficits, clinical signs of disorientation, current injecting drug use, current major depression according to Diagnostic and Statistical Manual of Mental Disorders (Trull et al. [@CR44]), neurologic or severe psychiatric conditions that affect cognition, and a history of opportunistic infection of the central nervous system within the last 2 years. The following data were collected at the time of the screening test and obtained from the prospective data collection of the Swiss HIV Cohort Study: age, education, gender, CDC stage, CD4 cell count, HIV viral load, co-infection with hepatitis C, co-medication, drug and alcohol consumption, history for cART, opportunistic diseases and syphilis. Medical history of thyroid or vitamin B12 deficiency was not reviewed.

Study procedures and examination tools {#Sec5}
--------------------------------------

Two study nurses were trained by a neuropsychologist on how to perform the screening battery according to standard procedures. The screening test consisted of a short questionnaire and seven selected neuropsychological tests based on theory-led principles and psychometric criteria, and it has already proven its value in a similar form in HIV-infected individuals (Carey et al. [@CR6]). The time needed to perform the short examination was recorded and its acceptance was evaluated by a feedback questionnaire for both patients and nurses.

Screening battery {#Sec6}
-----------------

Our screening battery comprised a questionnaire and a short examination of selective cognitive functions.

### 1. Questionnaire {#Sec7}

Following questions were asked to investigate cognitive functions: Do you frequently experience memory loss (e.g. do you forget the occurrence of special events even the more recent ones, appointments, etc.)? Do you feel that you are slower when reasoning, planning activities, or solving problems? Do you have difficulties in paying attention (e.g. to a conversation, a book, or a movie)? Patients could answer with 'never' , 'rarely' , 'sometimes' , 'often' or 'always'.

As individuals may overestimate or underestimate their own deficits when making subjective statements on cognitive losses (Hinkin et al. [@CR16]), we added two questions to increase the robustness of the subjective statements: one on everyday memory complaint because memory losses are frequently reported in this area (Woods et al. [@CR47]): Do you intend to do something and then you forget what it was (e.g. do you go into another room to fetch something and then forget what you wanted to get)? The second refers to whether friends or family made remarks on the individual's diminished cognitive skills: Do friends and/or members of your family tell you that your brain power has deteriorated?

The following two questions were asked to estimate whether there was a clinically relevant depression (Sacktor et al. [@CR33]): How often did you note little interest or pleasure in doing things over the past 2 weeks? How often did you experience feeling down, depressed or hopeless over the past 2 weeks? Patients could answer with 'not at all' , 'several days' , 'more than half the days' or 'nearly every day'.

### 2. Examination of selected cognitive functions {#Sec8}

Examination of selected cognitive functions consisted of seven brief tests to evaluate the following four domains: cognitive speed, memory, executive functions, and motor speed (Table [1](#Tab1){ref-type="table"}).Table 1**List of the seven tests used to evaluate the four domains (cognitive speed, memory, executive function and motor speed)**Cognitive domainTestVariablesCognitive speedTrail Making Test (TMT) ([@CR43]; Tombaugh et al. [@CR41]) part A and Bnumber of seconds to complete part A and part BDigit Symbol Test (DST) (Härting et al. [@CR14]; Aster et al. [@CR2])number of correct itemsMemorywordlist from the Multiple Sclerose Inventarium Cognition (Calabrese et al. [@CR5])number of correct items on 10 items learning and delayed recallExecutive functionsTMT ( [@CR43]; Tombaugh et al. [@CR41]) part A and Bnumber of seconds to complete part BMotor speedDST (Härting et al. [@CR14]; Aster et al. [@CR2])number of correct itemsGrooved Pegboard (Ruff & Parker [@CR32]) with dominant and non-dominant handnumber of seconds needed for completionTMT ( [@CR43]; Tombaugh et al. [@CR41]) part A and Bnumber of seconds to complete part A and part B

Following the above some tests counted for more than one domain, e.g., if the result in TMT part A was below 1 standard deviation, it counted in the domains \"cognitive speed\" and \"motor speed\".

The domains were considered as pathological, if one result in this domain was pathological, ie, a standard score below -1.0. The cognitive screening was considered pathological if the patient had deficits in two or more domains.

Nurses who administered the screening test were provided with a table indicating pathological performance. For example, a TMT part A result of more than 40 seconds from a subject aged between 40 and 49 years was considered pathological.

Acceptance of the screening battery {#Sec9}
-----------------------------------

A feedback questionnaire was filled out by each patient and the study nurse to evaluate the acceptance of the screening test. The questionnaire for patients comprised the following questions: Is the test too difficult? Are the instructions clear? Does the test respect your privacy? Is the screening reasonable? Is the test burdening? Are you interested in the results of the examination? Is the test too long? The questionnaire for study nurses included following questions: Is the test too difficult for patients? Is the screening reasonable? Is the test burdening for the study nurse? Is the test too long?

The patients and nurses could answer on a scale of 1--5 (not at all -- totally).

The questionnaire for nurses comprised also the following questions: Were there any ambiguities or uncertainties in the instructions? Were there any ambiguities or uncertainties in the evaluation? Were there any ambiguities or uncertainties in the interpretation?

The nurses were also able to attach comments or suggestions.

In-depth neuropsychological assessment {#Sec10}
--------------------------------------

Within one month, study participants were examined at the Basel Memory Clinic by a neuropsychologist using a comprehensive test battery to evaluate HAND. The examining neuropsychologist had no access to the results of the screening test.

The comprehensive neuropsychological examination, lasting for two hours, covered the following tasks: German version of the California Verbal Learning Test (Delis et al. [@CR10]) (when age ≥ 50 years) or the Verbal Learning and Memory Test (Helmstadter et al. [@CR15]) (when age \< 50 years); Figural Fluency (Regard et al. [@CR26]), modified Wisconsin Card Sorting Test (Nelson [@CR24]); Rey-Osterrieth Complex Figure (Rey [@CR28]); verbal fluency (semantic and phonemic) (Morris et al. [@CR23]), Color Trails 1 and 2 (D'Elia et al. [@CR9]); Boston Naming Test, 15 items (Nelson [@CR24]); Digit Span (Härting et al. [@CR14]; Aster et al. [@CR2]), Color Word Interference Test (Stroop [@CR39]) and Test of Attentional Performance (divided attention and alertness) (Fimm & Zimmermann [@CR12]).

Statistical analysis {#Sec11}
--------------------

Basic socio-demographic characteristics, CD4 cell count, and cART were compared using the Chi-square test or Fisher's exact test for categorical variables, and the Mann--Whitney test for continuous variables. All analyses were performed using STATA software version 11 for Windows (STATA Corp, College Station, Texas, USA).

Results {#Sec12}
=======

A total of 30 patients were included in this study between January 2011 and July 2011 at the HIV-Clinic of the University Hospital Basel. The median age was 52.5 years (interquartile range (IQR) 47--64) and most patients (87%) were males. One patient had a HIV viral load of 58 copies/mL, another one 65 copies/mL. Five patients had an elevated HIV viral load (range 86--3594 copies/mL) within 6 months before this investigation. The median CD4 cell count was 658 cells/μL (IQR 497--814); 11 patients (37%) had previously been diagnosed with an AIDS-defining infection, one of these suffering from cerebral toxoplasmosis 12 years before without clinically obvious neurological sequelae. Among co-morbidities, 3 patients (10%) had co-infection with hepatitis C, one patient had a history of transient ischemic attack many years before, and 5 patients (16.7%) had previously been treated for syphilis (stage I-II). Lumbar puncture yielding a negative syphilis serology of CSF was only done in one patient. We did not routinely carry out a lumbar puncture when patients had no clinical signs of involvement of the central nervous system between 6 months and 9 years before this investigation.

Prevalence of HAND {#Sec13}
------------------

Overall, 25 (83%) patients were diagnosed with HAND based on in-depth neuropsychological assessments. Of these, 16 patients (64%) had ANI, 8 (32%) MND, and 1 patient HAD. Among the 25 patients with HAND, only 9 patients (36%) were complaining of memory loss or difficulties to concentrate. The patient with HAD had HIV-infection CDC B3 with no relevant co-morbidity, in particular no obvious neurological disease. He was treated with an efavirenz-containing antiretroviral regimen. One of the 8 patients (13%) with MND and 5 (31%) of the 16 patients with ANI were also treated with an efavirenz-containing regimen. The 5 patients with a treated syphilis were diagnosed with ANI (n = 3), MND (n = 1), and no cognitive impairment (n = 1).

ANI was also diagnosed in one patient with stroke and in another patient with a history of cerebral toxoplasmosis. Also, two patients with occasional drug consumption (inhalative cocain, ketamin, methadon) had ANI. One patient with daily cannabis consumption had MND.

Detailed results of the in-depth neuropsychological examination are shown in Table [2](#Tab2){ref-type="table"}.Table 2**Raw scores of the in-depth neuropsychological assessment**MaxIQR 25%MedianIQR 75%RangeCalifornia Verbal Learning Test (n = 18):  Learning (trial 1--5)80434754.7526-63  Short Delay Free Recall167.39.512.01-16  Long Delay Free Recall167.311.012.01-16  Recognition Discriminability (%)100%90.993.295.581.2-95.5Verbal Learning and Memory Test (n = 12):  Learning (trial 1--5)7534.845.551.828-66  Delayed Recall15710112-14Figural Fluencyn.a.25.332.036.58-57Modified Wisconsin Card Sorting Test:  Categories66661-6  Perseverative Errorsn.a.0.00.53.00-8Rey-Osterrieth Complex Figure:  Copy3629.631.832.918.5-35.0  Immediate Recall3612.119.024.52.0-28.5  Delayed Recall3610.818.524.43.0-26.5Semantic Fluency (Animals), 1'n.a.16.5212412-33Phonemic Fluency (S-Words), 1'n.a.912166-19Color Trails 1240"333749.7519-126Color Trails 2240"0010-6Boston Naming Test1514151511-15Digit Span forward126784-11Digit Span backward1255.562-10Color Word Interference Test Time 1 (s)n.a.12131510-22Color Word Interference Test Time 3/1n.a.1.852.172.401.53-3.76Test of Attention Performance:  Divided Attention Auditive (ms), Mediann.a.516555631329-1109  Divided Attention Visual (ms), Mediann.a.758830898599-1234  Alertness (ms), Mediann.a.221237286186-634

Validity of questions addressing subjective cognitive impairment (SCI) {#Sec14}
----------------------------------------------------------------------

Twenty-five of the 30 patients were diagnosed with HAND based on the in-depth neuropsychological assessment. Among those, nine had reported a SCI (ie, sensitivity of SCI = 36%). Five patients had received a diagnosis of normal cognition after the in-depth neuropsychological assessment. Two of those had not reported SCI (ie, specificity of SCI = 40%). Thus, questions addressing SCI did not separate between those with and those without HAND.

Screening test battery {#Sec15}
----------------------

The screening battery revealed neurocognitive deficits in 17 of 30 (57%) patients (Figure [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}), corresponding to a sensitivity of 64% (95% confidence interval (CI 42-82%), a specificity of 80% (95% CI 28-99%), a PPV of 94% (95% CI 71-99%) and a NPV of 31% (95% CI 9-61%). Almost all patients with a pathological screening test (16/17, 94%) had a pathological result on their neuropsychological assessment. However, among the 13 patients with a normal screening result, 9 (69%) had HAND at the in-depth neuropsychological examination, i.e. were false negative. If only non-complaining patients (n = 18) were considered, i.e. patients not complaining of memory loss or difficulties in concentrating, the screening battery yielded a sensitivity of 75% (95% CI 48-93%) and a specificity of 100% (95% CI 19-100%), a PPV of 100% (95% CI 73-100%) and a NPV of 33% (95% CI 5-77%). If only patients with memory loss or difficulties to concentrate (n = 12) were considered, the screening battery had a sensitivity of 44% (95% CI 14-79%), specificity of 67% (95% CI 12-94%), a PPV of 80% (95% CI 29-97%) and a NPV of 29% (95% CI 5-71%). If results of the screening test battery were combined with those of the questionnaire (either one or both tests positive), a sensitivity of 84% (95% CI 64-95%), a specificity of 40% (95% CI 6-85%), PPV of 88% (95% CI 68-97%) and NPV of 33% (95% CI 5-77%) could be reached.Figure 1**Performance of the screening battery according to the presence of HAND at the in-depth neuropsychological examination.**

###### 

**Performance of the screening battery according to the presence of HAND at the in-depth neuropsychological examination**

                         In-depth neuropsychological assessment             
  ---------------------- ---------------------------------------- ---- ---- ----
  **Screening result**   positive                                 16   1    17
  sensitivity = 64%                                                         
  PPV = 94%                                                                 
  negative               9                                        4    13   
  specificity = 80%                                                         
  NPV = 31%                                                                 
                                                                  25   5    30

Comparison of results of the screening battery to those of the in-depth neurolopsychological assessment are shown in Table [3](#Tab3){ref-type="table"} and Figure [1](#Fig1){ref-type="fig"}.

Baseline characteristics of the study population according to results of the screening battery are shown in Table [4](#Tab4){ref-type="table"}. Test results were independent from demographic patients' characteristics, CD4 cell count, co-medication and cART. The overall duration of the screening test was 25 minutes (IQR 23--29), shorter if the patient had a normal neuropsychological assessment (21 minutes, IQR 20--25).Table 4**General characteristics of the study population (n = 30) according to results of the screening battery**Pathological screening test N = 17Normal screening test N = 13p-valuen%n%Median Age, IQR5549-644943-610.201Males158811850.591Prior AIDS-defining condition6355380.579Median CD4 cell count, IQR565405-738695531-8910.187Median years of education, IQR1211-131312-130.336cART containing efavirenz6352150.212Co-medication with psychotropic drugs (antidepressants, antipsychotics)5292150.427Memory loss or difficulties to concentrate reported by the patient\*5297540.164Depressive symptoms\*212180.603Median duration of screening battery, minutes, IQR2525-292321-260.099\*According to the questionnaire.

Acceptance of the screening battery {#Sec16}
-----------------------------------

The overall acceptance of the screening battery was excellent. Most patients (83%) estimated the screening test as valuable and not worrisome, and were interested in the results. Most participants (97%) considered the instructions for the test given by the study nurses as clear and the test battery as not difficult or partly difficult in 43% and 57% of patients, respectively. Privacy was not affected by the test according to 93% of patients, and nobody reported that the test was too long. Study nurses also judged the screening battery as not too difficult for patients, valuable and not worrisome, and not too long.

Discussion {#Sec17}
==========

In this study, investigating a specific combination of tests comprising a short questionnaire and a battery of selected neuropsychological tests for mild neurocognitive deficits in 30 HIV-infected individuals receiving cART, we found a moderate sensitivity and specificity when comparing to the in-depth neuropsychological examination serving as the criterion standard. Importantly, we found a high acceptance rate by patients and nurses. The sensitivity and specificity for this screening battery was increased in patients not complaining of memory loss or difficulties in concentration. If we combined results of the screening battery with those from the questionnaire (either one or both tests positive) we reached a sensitivity of 84% with a PPV of 88% and a NPV of 33%, making this screening strategy, administered by nurses, a simple, well accepted tool to screen treated HIV-infected individuals for mild neurocognitive disorders.

The prevalence of HAND in our study population was high (83%). This is in agreement with other studies (Simioni et al. [@CR34]). This is remarkable since all patients were not of older age, had no major psychiatric diseases and were not currently injecting drug users. Also, almost all patients had experienced a long school and professional education. Furthermore, nearly all patients had a suppressed viral load and were immunologically stable under continuous cART.

We consider the two viral load measurements in two patients (58 copies/mL and 65 copies/mL, respectively) as technical blips, however, we cannot rule out a low level viral replication. Five patients had an elevated HIV viral load (range 86--3594 copies/mL) within 6 months before this investigation. The patient with 3594 copies/ml did not take his medication at this time. Within the last 3 months before the examination, however, the viral load was suppressed.

Importantly, we could neither find any association with a cART regimen, in particular with efavirenz-based cART, nor with co-morbidities possibly affecting the neurocognitive performance. Interestingly, objective evidence of HAND was slightly more frequent in patients without complaints suggesting that an easy screening tool is very valuable before neuropsychological examination with more sophisticated instruments. Complaints about memory loss and difficulties to concentrate are difficult to interpret and also frequently reported by HIV-negative individuals (20-70%) without objective cognitive impairment (St John & Montgomery [@CR37]; Reid & Maclullich [@CR27]).

One of the problems encountered with investigating a new screening battery is the lack of a clear criterion standard. However, the in-depth neuropsychological examination has been well validated for cognitive assessment. The search for a good, easy-to-perform screening test is still justified, as the international HDS (Sacktor et al. [@CR33]) and the HDS (Power et al. [@CR25]) that are widely used as screening tests to identify individuals at risk for HAD (Sacktor et al. [@CR33]), are not enough sensitive to detect mild forms of neurocognitive deficits. However, the HIV dementia scale with a cut-off of 14 points was shown to have a sensitivity of 83%, specificity of 63% and a PPV of 92% to detect HAND in patients with complaints and a sensitivity of 88%, specificity of 67% and PPV of 82% in non-complaining patients (Simioni et al. [@CR34]). As a preliminary but encouraging result of this pilot study, our screening battery showed a similar accuracy as the HDS. An advantage may be that our screening battery does not comprise the anti-saccadic eye movement task, which can be challenging for the examiner. In addition to using cognitive tests only it incorporates the information about the patient\'s subjective cognitive impairment. Importantly, our approach to improve the screening for HAND requires a great deal of further work. In line with the suggestions outlined by Kamminga et al. ([@CR20]), at least the following points need to be addressed: (a) use of a representative sample of the HIV population, (b) inclusion of a control (HIV-) group with similar characteristics to optimally assess HAND specificity, (c) a more explicit rationale for screen impairment criteria, (d) reporting of all standard criterion validity indexes, (e) reporting of construct validity, and (f) assessing the longitudinal validity of the screening tool including correction for practice effects. Moreover, acceptability was excellent by patients and nurses.

We acknowledge some limitations: First, the number of patients was too small to draw conclusions regarding specific associations for neurocognitive deficits and cART regimen, e.g. efavirenz-based treatment that may impact on the central nervous system, or specific co-morbidities. Second, we did not perform MRI examinations of the brain nor lumbar punctures to exclude other causes of neurocognitive impairment than HIV. Third, the HIV dementia scale (Sacktor et al. [@CR33]) was not performed in our study population, so that a direct comparison with our screening test was not possible. Forth, the use of the same variable to assess different cognitive domains is problematic. This variable receives an unjustified importance and may lead to invalid results. Furthermore, combining the results of a screening battery with a questionnaire for subjective cognitive impairment is not in line with the Frascati criteria (Antinori et al. [@CR1]). However, this more comprehensive screening approach will allow the medical staff to detect not only patients with HAND, but also others, who might be in need of medical care, which in our view is an advantage.

In our study the prevalence of HAND was high. This may be due to the fact that patients with HCV co-infection, history of ischemic stroke, drug use and previous cerebral opportunistic infections were included in this study.

Drug use was assessed by self-report. We acknowledge self-report and potential interference of drug use as a limitation. Future research should also exclude patients with occasional drug consumption.

This study also has several strengths: First, this is the first study investigating a short screening battery with selected neuropsychological tests that were administered by nurses. Second, all 30 patients were underwent comprehensive neuropsychological assessments. Third, the fact that all patients were participating in the prospective Swiss HIV Cohort Study enabled us to assess important co-morbidities such as depression or syphilis and the corresponding treatments.

Conclusion {#Sec18}
==========

In conclusion, our study demonstrates that screening for neurocognitive deficits is likely to identify milder forms of cognitive disorders even in non-complaining patients. A short questionnaire combined with a small battery of selected neuropsychological tests is a short, easy-to-perform screening tool for HIV-infected individuals.

**Competing interest**

No author has a commercial or other association that might pose a conflict of interest.

**Authors' contribution**

DF planned and initiated the study, examined the patients, analysed the data, wrote the initial draft. UK planned and initiated the study, examined the patients, analysed the data. LE analysed the data. VW examined the patients. SN examined the patients. AUM planned and initiated the study, analysed the data. RS planned and initiated the study. MB planned and initiated the study, analysed the data. All authors read and approved the final manuscript.

We acknowledge all patients and study nurses who participated in this study. The authors wish to thank Prof. Dr. Manfred Berres for the statistical support and the Swiss HIV Cohort Study for support of the data collection.

This study was in part presented at the 11th International Conference on HIV drug therapy 2012, Glasgow, UK.

**Funding**

This study was supported by a research grant by Abbott Switzerland and by the Stiftung Forschung Infektionskrankheiten (SFI project \#37).
